{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:59:24Z","timestamp":1790168364374,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation Research"],"published-print":{"date-parts":[[2018,8,17]]},"abstract":"<jats:sec>\n            <jats:title>\n              <jats:underline>Rationale:<\/jats:underline>\n            <\/jats:title>\n            <jats:p>Allogeneic cardiac stem cells (AlloCSC-01) have shown protective, immunoregulatory, and regenerative properties with a robust safety profile in large animal models of heart disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:underline>Objective:<\/jats:underline>\n            <\/jats:title>\n            <jats:p>To investigate the safety and feasibility of early administration of AlloCSC-01 in patients with ST-segment\u2013elevation myocardial infarction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:underline>Methods and Results:<\/jats:underline>\n            <\/jats:title>\n            <jats:p>CAREMI (Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With STEMI and Left Ventricular Dysfunction) was a phase I\/II multicenter, randomized, double-blind, placebo-controlled trial in patients with ST-segment\u2013elevation myocardial infarction, left ventricular ejection fraction \u226445%, and infarct size \u226525% of left ventricular mass by cardiac magnetic resonance, who were randomized (2:1) to receive AlloCSC-01 or placebo through the intracoronary route at days 5 to 7. The primary end point was safety and included all-cause death and major adverse cardiac events at 30 days (all-cause death, reinfarction, hospitalization because of heart failure, sustained ventricular tachycardia, ventricular fibrillation, and stroke). Secondary safety end points included major adverse cardiac events at 6 and 12 months, adverse events, and immunologic surveillance. Secondary exploratory efficacy end points were changes in infarct size (percentage of left ventricular mass) and indices of ventricular remodeling by magnetic resonance at 12 months. Forty-nine patients were included (92% male, 55\u00b111 years), 33 randomized to AlloCSC-01 and 16 to placebo. No deaths or major adverse cardiac events were reported at 12 months. One severe adverse events in each group was considered possibly related to study treatment (allergic dermatitis and rash). AlloCSC-01 elicited low levels of donor-specific antibodies in 2 patients. No immune-related adverse events were found, and no differences between groups were observed in magnetic resonance\u2013based efficacy parameters at 12 months. The estimated treatment effect of AlloCSC-01 on the absolute change from baseline in infarct size was \u22122.3% (95% confidence interval, \u22126.5% to 1.9%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:underline>Conclusions:<\/jats:underline>\n            <\/jats:title>\n            <jats:p>AlloCSC-01 can be safely administered in ST-segment\u2013elevation myocardial infarction patients with left ventricular dysfunction early after revascularization. Low immunogenicity and absence of immune-mediated events will facilitate adequately powered studies to demonstrate their clinical efficacy in this setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:underline>Clinical Trial Registration:<\/jats:underline>\n            <\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT02439398.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circresaha.118.312823","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T09:09:56Z","timestamp":1529399396000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":84,"title":["Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction"],"prefix":"10.1161","volume":"123","author":[{"given":"Francisco","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"first","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Sanz-Ruiz","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, and Facultad de Medicina, Universidad Complutense, Madrid, Spain (R.S.-R., A.C.P., M.E.F.-S., R.Y., J.B.)"},{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bogaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Casado Plasencia","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, and Facultad de Medicina, Universidad Complutense, Madrid, Spain (R.S.-R., A.C.P., M.E.F.-S., R.Y., J.B.)"},{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Gilaberte","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Belmans","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University Hospitals and KU Leuven, Belgium (J.B., A.B., P.C., S.J.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Fern\u00e1ndez-Santos","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, and Facultad de Medicina, Universidad Complutense, Madrid, Spain (R.S.-R., A.C.P., M.E.F.-S., R.Y., J.B.)"},{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Charron","sequence":"additional","affiliation":[{"name":"HLA et Medicine (HLA-MED), H\u00f4pital Saint-Louis, Paris, France (D.C., R.A.-D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mulet","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Yotti","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, and Facultad de Medicina, Universidad Complutense, Madrid, Spain (R.S.-R., A.C.P., M.E.F.-S., R.Y., J.B.)"},{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Palacios","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Luque","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"S\u00e1daba","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Complejo Hospitalario de Navarra, Pamplona, Spain (R.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alberto","family":"San Rom\u00e1n","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"},{"name":"Department of Cardiology, Instituto de Ciencias del Coraz\u00f3n (ICICOR), Valladolid, Spain (J.A.S.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Larman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Policl\u00ednia Guipuzcoa, San Sebasti\u00e1n, Spain (M.L.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"},{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario, Salamanca, Spain (P.L.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sanch\u00eds","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"},{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario, Valencia, Spain (J.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel F.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"},{"name":"Department of Cardiology, IBIMA, UMA, UGC Coraz\u00f3n Hospital Cl\u00ednico Virgen de la Victoria, M\u00e1laga, Spain (M.F.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Claus","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University Hospitals and KU Leuven, Belgium (J.B., A.B., P.C., S.J.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Al-Daccak","sequence":"additional","affiliation":[{"name":"HLA et Medicine (HLA-MED), H\u00f4pital Saint-Louis, Paris, France (D.C., R.A.-D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleuterio","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Abad","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"DelaRosa","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Corc\u00f3stegui","sequence":"additional","affiliation":[{"name":"Coretherapix S.L.U.\/Tigenix Group Madrid, Spain (I.G., M.M., I.P., M.L., E.L., J.L.A., O.D., L.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bermejo","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, and Facultad de Medicina, Universidad Complutense, Madrid, Spain (R.S.-R., A.C.P., M.E.F.-S., R.Y., J.B.)"},{"name":"CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (F.F.-A., R.S.-R., A.C.P., M.E.F.-S., R.Y., J.A.S.R., P.L.S., J.S., M.F.J., J.B.)"},{"name":"Department of Cardiovascular Medicine, University Hospitals and KU Leuven, Belgium (J.B., A.B., P.C., S.J.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Janssens","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University Hospitals and KU Leuven, Belgium (J.B., A.B., P.C., S.J.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000558"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/tan.12614"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.11.029"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.052"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.175943"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.05.024"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq409"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.069"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310651"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0512-2"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60195-0"},{"key":"e_1_3_5_13_2","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre\u2013post designs.","volume":"62","author":"Liang KY","year":"2000","unstructured":"Liang, KY, Zeger, S. Longitudinal data analysis of continuous and discrete responses for pre\u2013post designs. Sankhya: The Indian Journal of Statistics (Series B). 2000;62:134\u2013148.","journal-title":"Sankhya: The Indian Journal of Statistics (Series B)"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2009.08.017"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.03.025"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61590-0"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.066"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx248"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu505"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.009"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2013-0104"},{"key":"e_1_3_5_23_2","volume-title":"Paper presented at: The American Heart Association Annual Scientific Sessions (AHA 2017)","author":"Henry TD","unstructured":"Henry, TD. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial Results. Paper presented at: The American Heart Association Annual Scientific Sessions (AHA 2017); 2017; Anaheim, CA."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308639"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.28726"},{"key":"e_1_3_5_26_2","first-page":"412","article-title":"LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.","volume":"37","author":"Traverse JH","year":"2010","unstructured":"Traverse, JH, Henry, TD, Vaughan, DE; Cardiovascular Cell Therapy Research Network. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37:412\u2013420.","journal-title":"Tex Heart Inst J"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht372"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.001009"},{"key":"e_1_3_5_29_2","first-page":"CD006536","article-title":"Stem cell treatment for acute myocardial infarction.","author":"Fisher SA","year":"2015","unstructured":"Fisher, SA, Zhang, H, Doree, C, Mathur, A, Martin-Rendon, E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015:CD006536.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.304346"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.06.019"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030798"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.06.011"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308937"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.879"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.049"}],"container-title":["Circulation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCRESAHA.118.312823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:48:06Z","timestamp":1715575686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCRESAHA.118.312823"}},"subtitle":["A Multicenter Randomized, Double-Blind, and Placebo-Controlled Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,8,17]]}},"alternative-id":["10.1161\/CIRCRESAHA.118.312823"],"URL":"https:\/\/doi.org\/10.1161\/circresaha.118.312823","relation":{},"ISSN":["0009-7330","1524-4571"],"issn-type":[{"value":"0009-7330","type":"print"},{"value":"1524-4571","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"2018-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}